Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Name: Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Published: 2010
License: Public Domain

Millennium Pharmaceuticals, Inc. · 2010

ClinicalTrials.gov · Datasets · License: Public Domain · 2010

Open Source ↗

drug-therapy ovarian-cancer

ovarian carcinoma, fallopian tube cancer, peritoneal cancer, breast carcinoma, recist: response evaluation criteria in solid tumors, oc: ovarian cancer, gcig: gynecologic cancer intergroup, breast carcinoma (phase 1), drug therapy, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Related documents